Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab TherapyPaolo A. Ascierto, Victoria Atkinson, Ewa Kalinka‐Warzocha et al.|JAMA Oncology|2018Cited by 345
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Victoria Atkinson, Georgina V. Long et al.|Journal of Clinical Oncology|2020Cited by 226
Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammationSara Bjursten, Max Levin, Zhiyuan Zhao et al.|EBioMedicine|2024Cited by 27
1261 Increased concentrations of S100B and neurofilament light chain in serum indicate checkpoint inhibitor-induced CNS inflammationSara Bjursten, MAX LEVIN, Ankur Pandita et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1
Serum Concentrations of S100B and Neurofilament Light Chain as Biomarkers for Checkpoint Inhibitor–Induced CNS InflammationSara Bjursten, MAX LEVIN, Ankur Pandita et al.|SSRN Electronic Journal|2023Cited by 0